Half-Year-Report 2020
(WorldNews Health)

h1 Half-Year Report 2019 h1 Half-Year Report 2019 A TO OUR SHAREHOLDERS 2 3 A To Our Shareholders Letter to Shareholders 4 Formycon AG Half-Year Report 2019 A TO OUR SHAREHOLDERS 4 5 Over recent years, Formycon has been a true pioneer in bio- similar development." Dr. Carsten Brockmeyer CEO Dear Shareholders, The new drug class Biosimilars, still in its youth, continues to establish itself in the market and in medical practice. A recent analysis by ProBiosimilars, Germany`s working group for the biosimilars industry, shows that these are getting better and better at meeting the country`s healthcare needs. Within Germany, a biosimilar is already preferred to the reference drug in 38...